Page last updated: 2024-12-07

l 368899

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 368899: a selective oxytocin receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9872389
CHEMBL ID1253853
SCHEMBL ID17423276
MeSH IDM0228561
PubMed CID132857
SCHEMBL ID14829136
MeSH IDM0228561

Synonyms (30)

Synonym
unii-er33g946jt
148927-60-0
er33g946jt ,
butanamide, 2-amino-n-(7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo(2.2.1)hept-2-yl)-4-(methylsulfonyl)-, (1s-(1alpha,2alpha(r*),4beta))-
1-(((7,7-dimethyl-2-(2-amino-4-(methylsulfonyl)butyramido)bicyclo(2.2.1)heptan-1-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine
l-368899
l 368,899
gtpl2249
(2s)-2-amino-n-[(1s,4r,6s)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-6-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide
l-368,899
1-((7,7-dimethyl-2(s)-(2(s)-amino-4-(methylsulfonyl)butyramido)bicyclo[2,2,1]heptan-1(s)-yl)methylsulfonyl)-4-(2-methylphenyl)piperazine hydrochloride
CHEMBL1253853 ,
(s)-2-amino-n-((1s,2s,4r)-7,7-dimethyl-1-((4-o-tolylpiperazin-1-ylsulfonyl)methyl)bicyclo[2.2.1]heptan-2-yl)-4-(methylsulfonyl)butanamide
bdbm50326719
butanamide, 2-amino-n-((1s,2s,4r)-7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo(2.2.1)hept-2-yl)-4-(methylsulfonyl)-, (2s)-
SCHEMBL17423276
NCGC00485193-01
Q27895360
DTXSID80933504
(2s)-2-amino-n-[(1s,2s,4r)-7,7-dimethyl-1-({[4-(2-methylphenyl)-1-piperazinyl]sulfonyl}methyl)bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)butanamide
(2s)-2-amino-n-[(1s,2s,4r)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-2-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide
l-368,899hydrochloride
l-368899 free base
CS-0003693
HY-15008
AKOS040746043
l 368899
SCHEMBL14829136
(2s)-2-amino-n-[(1s,4r)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-2-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide
Q6456062

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Mean Cmax values were achieved at <1 hr at the low doses (25 mg/kg in rats and 5 mg/kg in dogs) and between 1 and 4 hr at the higher doses (100 mg/kg in rats and 33 mg/kg in dogs)."( Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Alvaro, RF; Chiu, SH; Colletti, AE; Feeney, WP; Miller, RR; Thompson, KL; Vincent, SH; Wallace, MA, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The presence of active N-demethylated metabolites of two other equipotent compounds in rats and dogs was found to be the major factor responsible for the discrepancy between oral bioavailability and efficacies observed for these 2 compounds."( The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development.
Alvaro, RF; Chiu, SH; Huskey, SW; Pettibone, DJ; Stearns, RA; Thompson, KA; Vincent, SH,
)
0.13
" In animal studies, L-368,899 was shown to be a potent and selective OT antagonist and was orally bioavailable in rats, dogs and chimpanzees."( Progress in the development of oxytocin antagonists for use in preterm labor.
Bock, MG; Evans, BE; Guidotti, M; Harrell, CM; Jasper, JR; Lis, EV; O'Brien, JA; Pettibone, DJ; Reiss, DR; Woyden, CJ, 1995
)
0.29
" Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs."( Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Alvaro, RF; Chiu, SH; Colletti, AE; Feeney, WP; Miller, RR; Thompson, KL; Vincent, SH; Wallace, MA, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Under this condition, we constructed dose-response curves analyzing the effect of local spinal oxytocin (0."( Oxytocin inhibits the rat medullary dorsal horn Sp5c/C1 nociceptive transmission through OT but not V
Condés-Lara, M; García-Boll, E; González-Hernández, A; Martínez-Lorenzana, G, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)Ki0.59000.00040.43453.9811AID513686; AID751375
Oxytocin receptorHomo sapiens (human)Ki0.01300.00010.07180.9780AID751376
Vasopressin V1a receptorRattus norvegicus (Norway rat)IC50 (µMol)0.37000.08201.04775.0000AID751378
Vasopressin V1a receptorRattus norvegicus (Norway rat)Ki0.11000.00080.03000.1100AID513685
Vasopressin V1a receptorHomo sapiens (human)Ki0.18000.00020.62357.0300AID513684; AID751359
Oxytocin receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00890.00890.29920.7800AID751379
Vasopressin V2 receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.57000.00050.06380.5700AID751377
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Ki0.20000.00030.97919.7000AID513687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID751359Binding affinity to human liver V1A receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513682Displacement of [3H]-oxytocin from oxytocin receptor in human uterus tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513685Displacement of [3H]vasopressin from vasopressin V1a receptor in rat liver tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513689Inhibition of oxytocin-induced uterine contraction in intraduodenally dosed rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513690Oral bioavailability in rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513691Oral bioavailability in human2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513684Displacement of [3H]vasopressin from vasopressin V1a receptor in human liver tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID751378Inhibition of rat liver V1a receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513687Displacement of [3H]vasopressin from vasopressin V2 receptor in rat kidney tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID751376Binding affinity to human OT receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513692Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V1a receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513686Displacement of [3H]vasopressin from vasopressin V2 receptor in human kidney tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513683Displacement of [3H]-oxytocin from oxytocin receptor in rat uterus tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID751377Inhibition of rat kidney V2 receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID751361Oral bioavailability in rat2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513695Oral bioavailability in chimpanzee2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID751375Binding affinity to human V2 receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID751379Inhibition of rat uterus OT receptor2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513696Aqueous solubility of the compound at pH 5.22010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513694Oral bioavailability in dog2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513693Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V2 receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID751362Oral bioavailability in dog2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.
AID513688Inhibition of oxytocin-induced uterine contraction in iv dosed rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1995Life sciences, , Volume: 57, Issue:24
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (10.20)18.2507
2000's7 (14.29)29.6817
2010's33 (67.35)24.3611
2020's4 (8.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.80 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews2 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other44 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]